Global B-cell Maturation Antigen (BCMA) Targeted Therapies Market, by Product Type (CAR-T cell, Bispecific Antibodies, and Antibody Drug Conjugates), by Indication (Acute Lymphoblastic Leukemia, and Multiple Myeloma), and by Geography - Insights, Size, Share, Opportunity Analysis, and Industry Forecast till 2025

  • Published On : Oct 2017 |
  • Pages : 130 Pages |
  • Format : CMI Insight PPT Format CMI Insight PDF Format

B-Cell Maturation Antigen (BCMA) Targeted Therapy – An innovative therapy for multiple myeloma

Multiple myeloma (MM) refers to a clonal plasma cell malignant neoplasm that is observed in the soft, spongy tissue of the bone marrow. The plasma cells are a crucial part of the immune system, which helps to fight against various types of infections and several other diseases. Multiple myeloma is a type of cancer formed by malignant plasma cells and characterized by low blood counts, renal failure, hypercalcemia, immune suppression, monoclonal gammopathy, and anemia. Moreover, multiple myeloma remains as an incurable disease. According to the American Cancer Society, in 2017, an estimated 30,280 a­­­­­dults (17,490 men and 12,790 women) in the U.S. will be diagnosed with multiple myeloma and 12,590 deaths (6,660 men and 5,930 women) will occur in U.S. in 2017 due to multiple myeloma disease. According to the National Center for Biotechnology Information 2014, multiple myeloma represents 8.2% of all blood cancers in Africa.

B-Cell maturation antigen (BCMA) is a cell surface protein that is expressed on the malignant plasma cells. The expression profiles exhibited by TACI and BAFF-R are comparatively lower than that of the BCMA in multiple myeloma patients. Also, these antigens are hardly detected in the malignant plasma cells thus suggesting BCMA to be a standard choice over the other targeting antigens. The expression of BCMA gradually increases with the progression from normal Monoclonal Gammopathy of Undetermined Significance (MUGA) to smoldering multiple myeloma (SMM) to active multiple myeloma. This unique expression profile is exhibited only by the BCMA cells as they have a very restricted expression pattern and are unexpressed in normal human tissues. BCMA-target therapy has thus gained traction for cancer treatment and will be the choice of treatment especially for multiple myeloma. BCMA possess co-immunoprecipitation property with a master transcription factor (IRF-4) that are mediated for myeloma cell survival. BCMA targeted therapies actively involve three major types of immunotherapies on the basis of product class namely, chimeric antigen receptor T-cells (CAR T Cells), bispecific antibodies, and antibody drug conjugates (ADCs).

However, high cost involved in multiple combinational drug as well as maintenance therapy is expected to hinder growth of the BCMA targeted therapies market.

Key players in the market are focused on product development and conducting preclinical and clinical trials to assess the efficacy of these products mainly through the safety profile offered by these therapies.

Fig. 1. B-Cell Maturation Antigen (BCMA) targeted pipeline products

B-Cell Maturation Antigen Market | Coherent Market Insights

Source: Coherent Market Insights 2017

Increasing number of pipeline products is expected to boost growth of the B-cell maturation Antigen (BCMA) targeted therapies market

Market players are actively investing in research and development of novel multiple myeloma therapies. These therapies include chimeric antigen receptor T cells, antibody-drug conjugate, and Bi-specific antibodies. For instance, GlaxoSmithKline Plc. (GSK2857916) is developing the antibody drug conjugate drug for relapsed/refractory multiple myeloma and other advanced hematologic malignancies expressing BCMA. The robust pipeline of therapies for the treatment of multiple myeloma is expected to boost growth of the B-cell maturation Antigen (BCMA) targeted therapies market.

Increasing number of recurring cases of multiple myeloma is expected to drive growth of the B-cell maturation Antigen (BCMA) targeted therapies market

The patients undergoing chemotherapy and radiation therapy are at high risk of recurrence of cancer as they develop resistance to these therapy. At present there are no treatment options for patients with recurrent cancer and hence the BCMA targeted therapies provide breakthrough therapeutic options for the treatment of relapsed or refractory multiple myeloma, where the existing treatment modalities have proved to be clinically inefficient.

Key players operating in the development of B-cell maturation antigen (BCMA) targeted therapies market are Celgene Corporation, GlaxoSmithKline plc., Novartis AG, Juno Therapeutics, Gilead Sciences. Inc., Amgen Inc., Affimed N.V, Poseida Therapeutics, Inc., and Autolus Ltd.

Recurrence of multiple myeloma has been a highly prevalent health condition, which requires novel and effective immunotherapeutic treatment. According to Leukemia Research by Elsevier, as of 2014, the incidence of multiple myeloma is estimated to be around 120,000 cases per year, with a global prevalence of over one million cases. B-cell maturation antigen (BCMA), is a cell surface protein that is expressed on the malignant plasma cells. This cell surface protein has emerged as a very selective antigen targeted therapy for the treatment of multiple myeloma. BCMA targeted therapies actively involve three major types of immunotherapies on the basis of product class namely, chimeric antigen receptor T-cells (CAR T Cells), bispecific antibodies, and antibody drug conjugates (ADCs). These advanced therapies are expected to improve the survival rate of multiple myeloma patients.

Market Dynamics

Increasing prevalence of multiple myeloma is expected to favor the B-cell maturation antigen (BCMA) targeted therapies market worldwide. According to the American Cancer Society, U.S., in 2016, the lifetime risk for multiple myeloma was around 1 in 143 people, with an estimated 30,280 adults (17,490 men and 12,790 women) diagnosed with multiple myeloma. The mortality rate of the disease was estimated to be 12,590 (6,660 men and 5,930 women) in 2016. Key players are actively involved in the development of immunotherapies targeting BCMA for the treatment of multiple myeloma, the demand for which is expected to increase, This in turn, is expected to boost development of novel treatments for relapsed or refractory myeloma. Furthermore, patients undergoing existing drug therapies are prone to the risk of relapse. Hence, B-cell maturation antigen targeted therapy, which primarily addresses this concern is expected to gain rapid traction.

Market Taxonomy

This report segments the global B-cell maturation antigen (BCMA) targeted therapies market on the basis on product type, indication, and regions. On the basis of product type, the market is segmented into antibody drug conjugates, CAR-T cells, bispecific antibodies. On the basis of indication, the market is segmented into acute lymphoblastic leukemia and multiple myeloma. For comprehensive understanding of market dynamics, the global B-cell Maturation Antigen (BCMA) targeted therapies market is analyzed across key geographical regions namely, North America, Europe, Asia Pacific, Latin America, Africa, and Middle East. Each of these regions is analyzed on the basis of market findings across major countries in these regions for a macro-level understanding of the market.

Key Features of the Study:

  • This report provides in-depth analysis of the global B-cell maturation antigen (BCMA) targeted therapies market and provides pipeline analysis for the same
  • It elucidates potential opportunity across different segments and explains attractive investment proposition matrix for this market. It provides valuable insights about market drivers, restraints, opportunities, impact analysis, key developments, and competitive landscape
  • It profiles leading players in the global B-cell maturation antigen (BCMA) targeted therapies market based on the following parameters – company overview, financial performance, product pipeline, geographical presence, and key developments
  • Key companies covered as a part of this study include Celgene Corporation, GlaxoSmithKline plc, Novartis AG, Juno Therapeutics, Gilead Sciences. Inc., Amgen Inc., Affimed N.V, Poseida Therapeutics, Inc., and Autolus Ltd
  • Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future BCMA targeted therapies product launch, market expansion, and marketing tactics
  • The global BCMA targeted therapies market report caters to various stakeholders in this industry including, investors, suppliers, manufacturers, distributors, new entrants, and financial analysts
  • Stakeholders would have ease in decision-making through the various strategy matrices used in analyzing the B-Cell maturation antigen (BCMA) targeted therapies market

Detailed Segmentation:

  • Global B-cell Maturation Antigen (BCMA) Targeted Therapies Market, By Product Type:
    • Antibody Drug Conjugates
    • CAR-T Cells
    • Bispecific Antibodies
  • Global B-cell Maturation Antigen (BCMA) Targeted Therapies Market, By Indication:
    • Acute Lymphoblastic Leukemia
    • Multiple Myeloma
  • Global B-cell Maturation Antigen (BCMA) Targeted Therapies Market, By Region:
    • North America
      • Overview
      • Epidemiology
    • Latin America
      • Overview
      • Epidemiology
    • Europe
      • Overview
      • Epidemiology
    • Asia Pacific
      • Overview
      • Epidemiology
    • Middle East
      • Overview
      • Epidemiology
    • Africa
      • Overview
      • Epidemiology
  • Company Profiles
    • Celgene Corporation *
      • Company Overview
      • Product Portfolio
      • Financial Performance
      • Key Strategies
      • Recent Developments
    • GlaxoSmithKline plc.
    • Novartis AG
    • Juno Therapeutics
    • Gilead Sciences. Inc
    • Amgen Inc
    • Affimed N.V
    • Poseida Therapeutics, Inc.
    • Autolus Ltd

 “*” marked represents similar segmentation in other categories in the respective section.

Table of Contents

  1. Research Objective and Assumption
    • Research Objectives
    • Assumptions
    • Abbreviations
  2. Market Purview
    • Report Description
    • Market Snapshot
  3. Market Dynamics, Opportunity, and Pipeline Analysis
    • Market Dynamics
      • Drivers
      • Restraints
      • Market opportunity
    • Pipeline Analysis
    • Targeted therapies developed till now
    • Epidemiology
  4. Global B-cell Maturation Antigen (BCMA) Targeted Therapies Market, By Product Type
    • Introduction
    • Antibody Drug Conjugates
      • Research Details
    • CAR- T cells
      •  Research Details
    • Bispecific Antibodies
      •  Research Details
  5. Global B-cell Maturation Antigen (BCMA) Targeted Therapies Market, By Indication
    • Introduction
    • Acute Lymphoblastic Leukemia
      • Overview
    • Multiple Myeloma
      • Overview
  6. Global B-cell Maturation Antigen (BCMA) Targeted Therapies Market, By Regions
    • Introduction
      • Addressable Market
    • North America
      • Overview
      • Epidemiology
    • Latin America
      • Overview
      • Epidemiology
    • Europe
      • Overview
      • Epidemiology
    • Asia Pacific
      • Overview
      • Epidemiology
    • Middle East
      • Overview
      • Epidemiology
    • Africa
      • Overview
      • Epidemiology
  7. Company Profiles
    • Celgene Corporation*
      • Company Overview
      • Product Portfolio
      • Financial Performance
      • Recent Developments/Updates
      • Strategies
    • GlaxoSmithKline plc.
      • Company Overview
      • Product Portfolio
      • Financial Performance
      • Recent Developments/Updates
      • Strategies
    • Novartis AG
      • Company Overview
      • Product Portfolio
      • Financial Performance
      • Recent Developments/Updates
      • Strategies
    • Juno Therapeutics
      • Company Overview
      • Product Portfolio
      • Financial Performance
      • Recent Developments/Updates
      • Strategies
    • Gilead Sciences. Inc
      • Company Overview
      • Product Portfolio
      • Financial Performance
      • Recent Developments/Updates
      • Strategies
    • Amgen Inc
      • Company Overview
      • Product Portfolio
      • Financial Performance
      • Recent Developments/Updates
      • Strategies
    • Affimed N.V
      • Company Overview
      • Product Portfolio
      • Financial Performance
      • Recent Developments/Updates
      • Strategies
    • Poseida Therapeutics, Inc.
      • Company Overview
      • Product Portfolio
      • Financial Performance
      • Recent Developments/Updates
      • Strategies
    • Autolus Ltd
      • Company Overview
      • Product Portfolio
      • Financial Performance
      • Recent Developments/Updates
      • Strategies
    • Analyst Views
  8. Section
    • References
    • Research Methodology
    • About Us and Sales Contact

Choose License Type

"How Can I Help You" ?

Finding it difficult to find the research that would cater to your business demands? Give us a chance to help you. One of our Research Consultants will connect to provide a customized solution.

[email protected]

Key Benefits

  • Custom Research Solution

    Talk to our research consultant to design an exclusive report as per your research needs.

  • Customer Fulfilment

    We aim to fulfil client's research demands with tailored research solutions.

  • Quick Turnaround Time Reports

    We aim to provide research studies in quickest turnaround time and in a much cost effective manner.

  • 360-degree Approach

    We cover each industry from supply and demand side with an aim to provide a most holistic research study.

  • Assured Quality

    We strive to provide most accurate and reliable research findings in our research reports.